Home › Companies › MADRIGAL PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and MADRIGAL PHARMACEUTICALS INC.’s Form 8-K, filed June 27, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 25, 2024: 6 items on MADRIGAL PHARMACEUTICALS INC.’s Form 8-K, filed June 27, 2024: 3 elected · 3 approved.
Notable dissent: 1 director (12.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore MADRIGAL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are MADRIGAL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bill Sibold | 16,222,905 | -- | -- | 154,896 | 2,188,174 | 99.1% | Elected | — |
| Elect Director: Rebecca Taub, M.D. | 16,045,750 | -- | -- | 332,051 | 2,188,174 | 98% | Elected | — |
| Elect Director: Fred B. Craves, Ph.D. | 14,311,451 | -- | -- | 2,066,303 | 2,188,221 | 87% | Elected | — |
| 2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 18,444,828 | 110,517 | 10,630 | -- | -- | 99.4% | Approved | — |
| 3. The compensation of the Company's named executive officers as described in the Proxy Statement | 15,585,020 | 781,212 | 11,522 | -- | 2,188,221 | 95% | Approved | — |
| 4. An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2035, as described in the Proxy Statement | 15,941,045 | 428,537 | 8,219 | -- | 2,188,174 | 97% | Approved | — |
Source: MADRIGAL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 27, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
288 asset managers disclosed a vote on at least one MADRIGAL PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Description as filed by funds: Re-election of Class II directors: Bill Sibold
MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bill Sibold”): 16,222,905 for, 154,896 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 1,772,021 | 0 | 0 | 0 | For |
| Vanguard | 1,675,430 | 0 | 0 | 0 | For |
| T. Rowe Price | 587,672 | 0 | 0 | 0 | For |
| BlackRock | 390,103 | 0 | 0 | 0 | For |
| Artisan | 251,283 | 0 | 0 | 0 | For |
| Charles Schwab | 123,656 | 0 | 0 | 0 | For |
| American Century | 91,230 | 0 | 0 | 0 | For |
| Fidelity | 76,653 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 54,469 | 0 | 0 | 0 | For |
| Lord Abbett | 54,435 | 0 | 0 | 0 | For |
| TIAA | 49,103 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 42,402 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 0 | 38,632 | Withhold |
| Pacific Life | 36,870 | 0 | 0 | 0 | For |
| Invesco | 35,339 | 0 | 0 | 0 | For |
| Brighthouse | 35,164 | 0 | 0 | 0 | For |
| State Street | 31,129 | 0 | 0 | 0 | For |
| Equitable | 30,800 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 30,140 | 0 | 0 | 0 | For |
| Principal | 1,732 | 0 | 0 | 27,194 | Mixed |
| Jackson National | 27,935 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 27,112 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,016 | 0 | 0 | 0 | For |
| Waddell & Reed | 22,182 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 20,392 | 0 | 0 | 0 | For |
Fund voting reports, all 80 managers: 5,715,165 for, 67,243 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 249,759 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 249,759 for.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Re-election of Class II directors: Fred B. Craves, Ph.D.
MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Fred B. Craves, Ph.D.”): 14,311,451 for, 2,066,303 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 1,772,021 | 0 | 0 | 0 | For |
| Vanguard | 1,596,441 | 0 | 0 | 78,989 | For |
| T. Rowe Price | 587,672 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 390,103 | Withhold |
| Artisan | 251,283 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 123,656 | Withhold |
| American Century | 91,230 | 0 | 0 | 0 | For |
| Fidelity | 70,387 | 0 | 0 | 6,266 | Mixed |
| OLD WESTBURY FUNDS INC | 54,469 | 0 | 0 | 0 | For |
| Lord Abbett | 54,435 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 49,103 | Withhold |
| JANUS ASPEN SERIES | 42,402 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 0 | 38,632 | Withhold |
| Pacific Life | 31,865 | 0 | 0 | 5,005 | Mixed |
| Invesco | 0 | 0 | 0 | 35,339 | Withhold |
| Brighthouse | 12 | 0 | 0 | 35,152 | Withhold |
| State Street | 67 | 0 | 0 | 31,062 | Withhold |
| Equitable | 3,090 | 0 | 0 | 27,710 | Mixed |
| Delaware/Macquarie | 0 | 0 | 0 | 30,140 | Withhold |
| Principal | 1,732 | 0 | 0 | 27,194 | Mixed |
| Jackson National | 0 | 0 | 0 | 27,935 | Withhold |
| AIG/SunAmerica | 27,112 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,016 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 22,182 | Withhold |
| ALGER FUNDS II | 0 | 0 | 0 | 20,392 | Withhold |
Fund voting reports, all 80 managers: 4,729,985 for, 1,052,423 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 249,759 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 249,759 for.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Re-election of Class II directors: Rebecca Taub, M.D.
MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Rebecca Taub, M.D.”): 16,045,750 for, 332,051 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 1,772,021 | 0 | 0 | 0 | For |
| Vanguard | 1,675,430 | 0 | 0 | 0 | For |
| T. Rowe Price | 587,672 | 0 | 0 | 0 | For |
| BlackRock | 390,103 | 0 | 0 | 0 | For |
| Artisan | 251,283 | 0 | 0 | 0 | For |
| Charles Schwab | 123,656 | 0 | 0 | 0 | For |
| American Century | 91,230 | 0 | 0 | 0 | For |
| Fidelity | 76,653 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 54,469 | 0 | 0 | 0 | For |
| Lord Abbett | 54,435 | 0 | 0 | 0 | For |
| TIAA | 49,103 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 42,402 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 0 | 38,632 | Withhold |
| Pacific Life | 36,870 | 0 | 0 | 0 | For |
| Invesco | 35,339 | 0 | 0 | 0 | For |
| Brighthouse | 35,164 | 0 | 0 | 0 | For |
| State Street | 72 | 0 | 0 | 31,057 | Withhold |
| Equitable | 30,800 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 30,140 | 0 | 0 | 0 | For |
| Principal | 1,732 | 0 | 0 | 27,194 | Mixed |
| Jackson National | 27,935 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 27,112 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,016 | 0 | 0 | 0 | For |
| Waddell & Reed | 22,182 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 20,392 | 0 | 0 | 0 | For |
Fund voting reports, all 80 managers: 5,671,061 for, 111,347 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 249,759 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 249,759 for.
Combines 5 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of our common stock available for issuance by 750,000 shares and extend its duration by 10 years until April 23, 2035.
MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“4. An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2”): 15,941,045 for, 428,537 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 4 : The Company's stockholders approved an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2035, as described in the Prox…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 1,772,021 | 0 | 0 | 0 | For |
| Vanguard | 1,675,430 | 0 | 0 | 0 | For |
| T. Rowe Price | 587,672 | 0 | 0 | 0 | For |
| BlackRock | 390,103 | 0 | 0 | 0 | For |
| Artisan | 251,283 | 0 | 0 | 0 | For |
| Charles Schwab | 123,656 | 0 | 0 | 0 | For |
| American Century | 0 | 91,230 | 0 | 0 | Against |
| Fidelity | 76,653 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 54,469 | 0 | 0 | 0 | For |
| Lord Abbett | 54,435 | 0 | 0 | 0 | For |
| TIAA | 49,103 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 42,402 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 38,632 | 0 | 0 | 0 | For |
| Pacific Life | 36,870 | 0 | 0 | 0 | For |
| Invesco | 35,339 | 0 | 0 | 0 | For |
| Brighthouse | 35,164 | 0 | 0 | 0 | For |
| State Street | 31,124 | 5 | 0 | 0 | For |
| Equitable | 30,800 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 30,140 | 0 | 0 | 0 | For |
| Principal | 28,926 | 0 | 0 | 0 | For |
| Jackson National | 27,935 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 27,112 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 23,294 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,016 | 0 | 0 | 0 | For |
| Waddell & Reed | 22,182 | 0 | 0 | 0 | For |
Fund voting reports, all 81 managers: 5,704,196 for, 100,622 against, 884 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 249,759 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 249,759 for.
Combines 8 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: Advisory vote to approve executive compensation.
MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“3. The compensation of the Company's named executive officers as described in the Proxy Statement”): 15,585,020 for, 781,212 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 1,772,021 | 0 | 0 | 0 | For |
| Vanguard | 1,596,441 | 78,989 | 0 | 0 | For |
| T. Rowe Price | 587,672 | 0 | 0 | 0 | For |
| Artisan | 517,473 | 0 | 0 | 0 | For |
| BlackRock | 390,103 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 123,656 | 0 | 0 | Against |
| American Century | 0 | 91,230 | 0 | 0 | Against |
| Fidelity | 76,349 | 304 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 54,469 | 0 | 0 | 0 | For |
| Lord Abbett | 54,435 | 0 | 0 | 0 | For |
| TIAA | 49,103 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 42,402 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 38,632 | 0 | 0 | 0 | For |
| Pacific Life | 36,870 | 0 | 0 | 0 | For |
| Invesco | 35,339 | 0 | 0 | 0 | For |
| Brighthouse | 35,164 | 0 | 0 | 0 | For |
| State Street | 31,122 | 7 | 0 | 0 | For |
| Equitable | 30,800 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 30,140 | 0 | 0 | 0 | For |
| Principal | 28,926 | 0 | 0 | 0 | For |
| Jackson National | 27,935 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 27,112 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 23,294 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,016 | 0 | 0 | 0 | For |
| Waddell & Reed | 22,182 | 0 | 0 | 0 | For |
Fund voting reports, all 82 managers: 5,710,941 for, 361,339 against, 884 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 2,487,193 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 1,969,798 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 923,102 | 0 | 0 | 0 | For |
| T. Rowe Price | 741,349 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 536,622 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 420,953 | 0 | 0 | 0 | For |
| BlackRock | 363,890 | 1,976 | 0 | 0 | For |
| Rock Springs Capital Management LP | 285,931 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 249,759 | 0 | 0 | 0 | For |
| State Street | 224,130 | 28 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 196,995 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 175,883 | 0 | 0 | 0 | For |
| TCG Crossover Management, LLC | 149,283 | 0 | 0 | 0 | For |
| Fidelity | 147,109 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 125,365 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 123,668 | 0 | 0 | Against |
| ArrowMark Colorado Holdings LLC | 0 | 98,806 | 0 | 0 | Against |
| American Century | 0 | 94,071 | 0 | 0 | Against |
| Ensign Peak Advisors, Inc | 91,042 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 75,000 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 66,359 | 0 | 0 | 0 | For |
| Northern Trust | 63,629 | 10 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 62,261 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 61,427 | 0 | 0 | 0 | For |
| FRED ALGER MANAGEMENT, LLC | 3,918 | 55,738 | 0 | 0 | Mixed |
Institutional-manager reports, all 228 managers: 10,474,984 for, 588,684 against, 16 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Prior year: 99.9% for (June 15, 2023 meeting) ▼ 0.5 pts
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 18,444,828 for, 110,517 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JANUS INVESTMENT FUND | 1,772,021 | 0 | 0 | 0 | For |
| Vanguard | 1,675,430 | 0 | 0 | 0 | For |
| T. Rowe Price | 587,672 | 0 | 0 | 0 | For |
| BlackRock | 390,103 | 0 | 0 | 0 | For |
| Artisan | 251,283 | 0 | 0 | 0 | For |
| Charles Schwab | 123,656 | 0 | 0 | 0 | For |
| American Century | 91,230 | 0 | 0 | 0 | For |
| Fidelity | 76,653 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 54,469 | 0 | 0 | 0 | For |
| Lord Abbett | 54,435 | 0 | 0 | 0 | For |
| TIAA | 49,103 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 42,402 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 38,632 | 0 | 0 | 0 | For |
| Pacific Life | 36,870 | 0 | 0 | 0 | For |
| Invesco | 35,339 | 0 | 0 | 0 | For |
| Brighthouse | 35,164 | 0 | 0 | 0 | For |
| State Street | 31,124 | 5 | 0 | 0 | For |
| Equitable | 30,800 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 30,140 | 0 | 0 | 0 | For |
| Principal | 28,926 | 0 | 0 | 0 | For |
| Jackson National | 27,935 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 27,112 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 23,294 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,016 | 0 | 0 | 0 | For |
| Waddell & Reed | 22,182 | 0 | 0 | 0 | For |
Fund voting reports, all 81 managers: 5,802,154 for, 2,664 against, 884 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 249,759 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 249,759 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,875,427 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | JANUS INVESTMENT FUND | 8.92% |
| 2 | Vanguard | 8.43% |
| 3 | T. Rowe Price | 2.96% |
| 4 | Artisan | 2.60% |
| 5 | BlackRock | 1.96% |
| 6 | Charles Schwab | 0.62% |
| 7 | American Century | 0.46% |
| 8 | Fidelity | 0.39% |
| 9 | OLD WESTBURY FUNDS INC | 0.27% |
| 10 | Lord Abbett | 0.27% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 12.51% |
| 2 | BAKER BROS. ADVISORS LP | 9.91% |
| 3 | Avoro Capital Advisors LLC | 4.64% |
| 4 | T. Rowe Price | 3.73% |
| 5 | RTW INVESTMENTS, LP | 2.70% |
| 6 | RA CAPITAL MANAGEMENT, L.P. | 2.12% |
| 7 | BlackRock | 1.84% |
| 8 | Rock Springs Capital Management LP | 1.44% |
| 9 | Erste Asset Management GmbH | 1.26% |
| 10 | State Street | 1.13% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Entities Affiliated with Janus Henderson Group plc | 2,902,050 | 14.60% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Entities Affiliated with Avoro Capital Advisors LLC | 2,143,704 | 10.79% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Entities Affiliated with Baker Bros. Advisors LP | 2,143,704 | 10.79% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Julian Baker | 2,143,704 | 10.79% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Paul A. Friedman, M.D. | 2,057,550 | 10.35% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Rebecca Taub, M.D. | 2,057,550 | 10.35% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| Vanguard Group | 1,812,054 | 9.12% | Form 13F, quarter ended March 31, 2024 |
| Entities Affiliated with The Vanguard Group | 1,574,742 | 7.92% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
| BlackRock | 1,559,712 | 7.85% | Form 13F, quarter ended March 31, 2024 |
| Entities Affiliated with BlackRock, Inc. | 1,212,562 | 6.10% | Proxy statement (DEF 14A), proxy filed April 29, 2024 |
Percentages above are of 19,875,427 shares outstanding, as reported by MADRIGAL PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At MADRIGAL PHARMACEUTICALS INC.'s shareholder meeting held June 25, 2024, in the 2023-2024 proxy season, 288 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,847 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve executive compensation. — MADRIGAL PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: MADRIGAL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MADRIGAL PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
MADRIGAL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “MADRIGAL PHARMACEUTICALS (MDGL) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/madrigal-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.